Drugs based on well-known hormonal mechanisms involved in the pathogenesis of this cancer are still being actively developed, but more and more drugs are being implemented that target molecular targets related to carcinogenesis, such as the PI3K/AKT/mTOR pathway. This evidence concerns the gene AKT1 and cancer.